Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2016 - 2025)

Protalix BioTherapeutics has reported Total Non-Current Liabilities over the past 16 years, most recently at $7.6 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $7.6 million for Q4 2025, up 65.71% from a year ago — trailing twelve months through Dec 2025 was $7.6 million (up 65.71% YoY), and the annual figure for FY2025 was $7.6 million, up 65.71%.
  • Total Non-Current Liabilities for Q4 2025 was $7.6 million at Protalix BioTherapeutics, up from $7.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PLX hit a ceiling of $46.5 million in Q4 2021 and a floor of $4.4 million in Q1 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $7.5 million (2021), compared with a mean of $18.3 million.
  • Peak annual rise in Total Non-Current Liabilities hit 447.55% in 2021, while the deepest fall reached 88.77% in 2021.
  • Protalix BioTherapeutics' Total Non-Current Liabilities stood at $46.5 million in 2021, then fell by 26.93% to $34.0 million in 2022, then crashed by 84.31% to $5.3 million in 2023, then decreased by 14.06% to $4.6 million in 2024, then soared by 65.71% to $7.6 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $7.6 million (Q4 2025), $7.4 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.